Autopsy report · NCT00484536

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“The study was discontinued due to unfavorable interim analysis”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 3 years 2 months before it stopped.
232 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: UCB Pharma
Sponsor type: Industry
Conditions: Multiple Sclerosis
Interventions: CDP323; placebo; CDP323
Participants: 232
Sites: 71
Countries: Belgium, Canada, Finland, France, Germany, Hungary, Netherlands, Spain, Sweden, United Kingdom, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.